Use of posaconazole in the treatment of infective rhinocerebral mucormycosis

Journal of Laryngology and Otology

Volumn 124, Issue 12, 2010, Pages 1314-1317

  Kulendra, K ^a   Habibi, M ^a   Butler, C ^a   Clarke, P ^a   Howard, D ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

Amphotericin B; Brain; Mucorymycosis; Otorhinolaryngologic Surgical Procedures; Paranasal Sinuses; Posaconazole

Indexed keywords

ALANINE AMINOTRANSFERASE; AMOXICILLIN PLUS CLAVULANIC ACID; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; POSACONAZOLE;

ADULT; ARTICLE; BACTERIAL SINUSITIS; BONE NECROSIS; CASE REPORT; CRANIAL NEUROPATHY; DEBRIDEMENT; DIABETES MELLITUS; DIPLOPIA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EXOPHTHALMOS; FUNGAL SINUSITIS; HUMAN; HYPERTRANSAMINASEMIA; LIVER FUNCTION TEST; MALE; MAXILLA RESECTION; MUCORMYCOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ORBIT INFECTION; PARANASAL SINUS; PTOSIS; RHINOCEREBRAL MUCORMYCOSIS; RHIZOPUS; TISSUE NECROSIS; VIRUS CULTURE; VISUAL DISORDER;

ANTIFUNGAL AGENTS; BRAIN DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUCORMYCOSIS; ORBITAL DISEASES; PARANASAL SINUS DISEASES; RHIZOPUS; TRIAZOLES;

EID: 78649964696     PISSN: 00222151     EISSN: 17485460     Source Type: Journal    
DOI: 10.1017/S0022215110000678     Document Type: Article

References (19)

1. de Shazo RD, O'Brien M, Chaplin K, Soto-Aguilar M, Gardner L, Swain R. A new classification and diagnositic criteria for invasive fungal sinusitis. Arch Otolaryngol Head Neck Surg 1997;123:1181-8
2. Morgan J, Wamock DW. Fungi. In: Jones NJ, ed. Scott- Brown's Otolaryngology, Head and Neck Surgery. Oxford: Arnold, 2008;1:213-17
3. Peterson KL, Wang M, Canalis RF, Abemayor E. Rhinocerebral mucormycosis: Evolution of the disease and treatment options. Laryngoscope 1997;107:855-62
4. Strasser MD, Kennedy RJ, Adam RD. Rhinocerebral mucormycosis: Therapy with amphotericin B lipid complex. Arch Intern Med 1996;156:337-9
5. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000;30:851-6
6. Greenberg RN, Mullane K, van Burik JA, Raad I, Abzug MJ, Anstead G et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006;50: 126-33
7. Van Burik JA, Hare R, Solomon H, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: A retrospective summary of 91 cases. Clin Infect Dis 2006;43:376
8. Rodriguez MM, Serena C, Mariné M, Pastor FJ, Guarro J. Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae. Antimicrob Agents Chemother 2008;52: 3786-8
9. AmBisome. Summary of Product Characteristics. In: Http:// emc.medicines.org.uk/medicine/1236/SPC/AmBisome/ [30 July 2009]
10. Greenberg RN, Scott LI, Vaughn HH, Ribes JA. Zygomycosis (mucormycosis): Emerging clinical importance and new treatments. Curr Opin Infect Dis 2004;17: 517-25
11. Hosseini SMS, Borghei P. Rhinocerebral mucormycosis: Pathways of spread. Eur Arch Otorhinolaryngol 2005;262: 932-8
12. Tobon AM, Arango M, Fernandex D, Restrepo A. Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: Recovery after posaconazole therapy. Clin Infect Dis 2003;36:1488-91
13. Pardal Refoyo JL, Chocarro Martinez A, Brezmes Valdivieso MF, Parra Pérez C. Treatment review in rhinocerebral mucormycosis [in Spanish]. An Otorrinolaringol Ibero Am 1998;25:45-56
14. Streppel M, Bachmann G, ArnoldG, Damm M, Stennert E. Successful treatment of an invasive aspergillosis of the skull base and paranasal sinuses with liposomal amphotericin B and itraconazole. Ann Otol Rhinol Laryngol 1999;108: 205-7
15. Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Horwith G, Lee L et al. Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26:1383-96
16. Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare Ret al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006;50:2009-15
17. Ullmann AJ, Cornely OA, Burchardt A, Hachem R, Kontoyiannis DP, Töpelt K et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006;50:658-66
18. Ibrahim AS, Gebremariam T, Schwartz JA, Edwards JE Jr, Spellberg B. Posaconazole mono- or combination therapy for treatment of murine zygomycosis. Antimicrob Agents Chemother 2009;53:772-5
19. Garcia-Covarrubias L, Barrat DM, Bartlett R, Metzinger S, Van Meter K. Invasive aspergillosis treated with adjunctive hyperbaric oxygenation: A retrospective clinical series at a single institution. South Med J 2002;95:450-6